hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-08-27. Anything still debated is marked as such rather than presented as settled.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
=== Pharmacodynamics === Luvesilocin is a prodrug that is metabolized into 4-HO-DiPT. This metabolite is an analogue of the neurotransmitter serotonin and acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A receptor. Activation of the serotonin 5-HT2A receptor is thought to be specifically responsible for the hallucinogenic effects of serotonergic psychedelics. 4-HO-DiPT produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. In drug discrimination tests, 4-HO-DiPT fully substituted for the psychedelic drug DOM, with 5-fold lower potency than DOM and 2-fold lower potency than psilocin (4-HO-DMT). The drug activates basolateral amygdala (BLA) interneurons via the serotonin 5-HT2A receptor to enhance GABAergic inhibition of principal neurons in the BLA, which may mediate an anxiolytic effect of suppression of learned fear (fear extinction) in rodents.
=== Iron chelation === Multiple blood transfusions lead to severe iron overload, as the body eventually breaks down the hemoglobin in donated cells. This releases iron which it is unable to excrete. Iron overload may be treated by chelation therapy with the medications deferoxamine, deferiprone, or deferasirox. Deferoxamine is only effective as a daily injection, complicating its long-term use. Adverse effects include primary skin reactions around the injection site and hearing loss. Deferasirox and deferiprone are both oral medications, whose common side effects include nausea, vomiting and diarrhea.
In addition to the classical nuclear AR, bicalutamide has been assessed at the membrane androgen receptors (mARs) and found to act as a potent antagonist of ZIP9 (IC50 = 66.3 nM), whereas it does not appear to interact with GPRC6A. The affinity of bicalutamide for the AR is relatively low as it is approximately 30 to 100 times lower than that of DHT, which is 2.5- to 10-fold as potent as an AR agonist as testosterone in bioassays and is the main endogenous ligand of the receptor in the prostate gland. However, typical clinical dosages of bicalutamide result in circulating levels of the drug that are thousands of times higher than those of testosterone and DHT, allowing it to powerfully prevent them from binding to and activating the receptor. This is especially true in the case of surgical or medical castration, in which testosterone levels in the circulation are approximately 95% reduced and DHT levels in the prostate gland are about 50 to 60% reduced. In women, levels of testosterone are substantially lower (20- to 40-fold) than in men, so much smaller doses of bicalutamide (e.g., 25 mg/day in the hirsutism studies) are necessary. Blockade of the AR by bicalutamide in the pituitary gland and hypothalamus results in prevention of the negative feedback of androgens on the hypothalamic–pituitary–gonadal axis (HPG axis) in males and consequent disinhibition of pituitary luteinizing hormone (LH) secretion. This, in turn, results in an increase in circulating LH levels and activation of the gonadal production of testosterone and by extension production of estradiol.
=== 30 December === Thirty-five people were killed in an RSF drone strike on Dalang. The RSF and the SPLM-N (al-Hilu) seized the Al-Taqatu’ junction in South Kordofan, effectively cutting the main highway between Kadugli and Dalang. Both forces also seized SAF garrisons in Al-Taqatu’, Al-Balf, and Hajar Daliba.
Ortho Clinical Diagnostics (now QuidelOrtho) is an in vitro diagnostics company that made products and diagnostic equipment for blood testing. Ortho served two primary industries in the medical field: clinical laboratories, by producing platforms and assays that test for a variety of diseases, conditions, and substances; and immunohematology, by providing the means to ensure blood transfusion recipients receive appropriate and compatible blood. Johnson and Johnson acquired Eastman Kodak's Clinical Diagnostics Division in 1994 (to form Johnson & Johnson Clinical Diagnostics), which was then merged with Ortho Diagnostic Systems in 1997. QuidelOrtho's global corporate offices are in Raritan, New Jersey, while their global research and development center is in Rochester, New York. In 2014, The Carlyle Group purchased the company from Johnson & Johnson for $4.15 billion. Ortho Clinical Diagnostics now operated as an independent company, up until its acquisition by Quidel Corporation for $6 billion, on May 27, 2022.
Sources: en.wikipedia.org
Salvia divinorum is native to the Sierra Mazateca in Oaxaca, Mexico, where it is still used by the Mazatec, primarily to facilitate shamanic visions in the context of curing or divination. S. divinorum is one of several plant species with hallucinogenic properties that are ritually used by Mazatec shamans. In their rituals, the shamans use only freshly harvested S. divinorum leaves. They see the plant as an incarnation of the Virgin Mary, and begin the ritual with an invocation to Mary, Saint Peter, the Holy Trinity, and other saints. Ritual use traditionally involves being in a quiet place after ingestion of the leaf—the Maztec shamans say that "La Maria (S. divinorum) speaks with a quiet voice." It is also used in smaller amounts, as a diuretic, and to treat ailments including diarrhea, anemia, headaches, rheumatism, and a semi-magical disease known as panzón de borrego, or a swollen belly (literally, "lamb belly"). The history of the plant is not well known, and there has been no definitive answer to the question of its origin. Speculation includes Salvia divinorum being a wild plant native to the area; a cultigen of the Mazatecs; or a cultigen introduced by another Indigenous group. Botanists have also not been able to determine whether it is a hybrid or a cultigen.
== Interactions based on pharmacokinetics == Pharmacokinetics is the field of research studying the chemical and biochemical factors that directly affect dosage and the half-life of drugs in an organism, including absorption, transport, distribution, metabolism and excretion. Compounds may affect any of those process, ultimately interfering with the flux of drugs in the human body, increasing or reducing drug availability.
== Diagnosis == The vast majority of cats present with diabetes mellitus, the possibility of hypersomatotropism causing it is rarely considered until the diabetes becomes difficult to control. In cats with difficult to control diabetes mellitus, hypersomatotropism should be considered as a cause only after exclusion of other conditions that can impact insulin. Bitches with hypersomatotropism are usually presented 3–5 weeks after oestrus. It is not uncommon for owners to report symptoms relating to the diabetes mellitus as having occurred during the previous oestrous cycle, typically more mild and ending with anoestrus. Most abnormalities on common tests, such as complete blood count, urinalysis, and biochemistry profile, are due to the diabetes mellitus. Some cats with hypersomatotropism have hyperproteinaemia. One study found it to be the only parameter more frequent in cats with hypersomatotropism than cats with just diabetes mellitus. The common steps of diagnosis in cats involve presentation with diabetes mellitus, on examination either the acromegalic effects are noticed or they are not noticed and hypersomatotropism is not suspected until efforts to control the diabetes are proving difficult. Following this levels of growth hormone or IGF-1 are measured, if the results suggest hypersomatotropism it is then usually followed up with CT/MRI imaging to find the pituitary mass. In dogs the tentative diagnosis is made based on signs of acromegaly or diabetes mellitus alongside progestogen administration or dioestrus.
== Atrial fibrillation == Pulmonary vein isolation has been the mainstay of atrial fibrillation reduction, but in many cases there are other sources of arrhythmia, including the LoM. Use of ethanol through the VoM has been shown to be an effective way to reduce atrial fibrillation.
Management of invasive Lonicera japonica has been achieved through a variety of means. Small patches can be removed by hand, or using simple digging tools, but all plant parts including roots and rhizomes must be removed to prevent resprouting. Larger patches can be removed through repeated mowing, but application of herbicide is also recommended to prevent regrowth. There has been some study of using controlled burns to remove L. japonica, but the underground portion of the plant is usually able to survive and resprout, limiting the effectiveness of this method. Browsing by herbivores may limit its growth, but is unlikely to eliminate it.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.